Pacira BioSciences, Inc. (PCRX)
Days of sales outstanding (DSO)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| DSO | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —
The days of sales outstanding (DSO) for Pacira BioSciences, Inc. are not provided in the data for the periods spanning from March 31, 2020, to December 31, 2024. DSO is a valuable metric that measures the average number of days it takes for a company to collect payment after making a sale. It is calculated by dividing accounts receivable by average daily sales.
Without the specific DSO figures, we are unable to analyze the efficiency of Pacira BioSciences in collecting its accounts receivable. A lower DSO value typically indicates a faster collection of receivables, which can be a positive sign of effective credit management and liquidity. Conversely, a higher DSO could suggest potential issues with receivables management or customer creditworthiness.
It is recommended that investors and stakeholders monitor Pacira BioSciences' DSO closely in future financial reports to assess the company's effectiveness in managing its accounts receivable and overall financial health.
Peer comparison
Dec 31, 2024